Alzheimer’s disease (AD) remains one of the most pressing global health challenges, especially as aging populations continue to grow. The condition steadily erodes memory and thinking abilities, deeply affecting daily life. New treatments, including monoclonal antibodies such as lecanemab and donanemab, have offered some optimism by slowing cognitive decline. However, these therapies still fall short of reversing the disease or restoring normal brain function.
A recent review published in Science China Life Sciences by Professor Yan-Jiang Wang and colleagues explores why progress has been limited. The researchers argue that focusing on a single cause has not worked because Alzheimer’s is far more complex. It arises from the combined effects of amyloid-beta (Aβ) buildup, Tau protein tangles, genetic risk factors, aging-related changes, and broader health conditions. Because of this complexity, they suggest that future treatments must take a more comprehensive and coordinated approach.
Alzheimer’s Disease Involves Multiple Interconnected Factors
The review highlights several key areas that are reshaping how scientists understand Alzheimer’s.
Beyond Amyloid-Beta (Aβ)
Amyloid-beta has long been a central target in Alzheimer’s research, but treatments aimed only at this protein have produced limited results. Scientists are now paying closer attention to Tau hyperphosphorylation, a process that leads to the formation of neurofibrillary tangles and the loss of brain cells. Addressing both Aβ and Tau may be necessary to slow disease progression more effectively.
Genetic Risk and Emerging Gene Therapies
Genetics play a major role in determining Alzheimer’s risk. While APOE ε4 remains the most widely recognized genetic factor, researchers are identifying additional variants linked to specific populations. Advances in genome editing (CRISPR/Cas9) are also being explored as potential one-time treatments that could modify disease risk at its source.
Aging and Whole-Body Health Shape Alzheimer’s Progression
Aging as a Central Driver
Aging is the strongest risk factor for Alzheimer’s and involves a range of biological changes. These include declining mitochondrial function, the buildup of damaged cells, and increased DNA damage. The review points to “senolytic” therapies, which aim to remove aging glial cells, as a possible way to improve brain health and slow decline.
Systemic Health and the Gut-Brain Connection
Alzheimer’s is also influenced by conditions that affect the entire body. Issues such as insulin resistance, high blood pressure, and imbalances in gut bacteria can worsen disease processes. Researchers are investigating whether existing diabetes medications and therapies targeting the gut-brain axis could help reduce these effects.
Toward Integrated and Multi-Target Alzheimer’s Therapies
The authors emphasize the need to move away from “reductionist” thinking and toward “integrated strategies.” This shift involves developing treatments that target multiple aspects of the disease at once. It also includes using advanced laboratory models, such as human iPSC-derived organoids, to test new therapies more effectively. In addition, precision medicine approaches based on early biomarkers like plasma pTau217 could allow doctors to identify and treat Alzheimer’s earlier and more accurately.
“Success in defeating Alzheimer’s hinges on interdisciplinary collaboration and holistic innovation,” the authors conclude. Their findings outline a path forward, suggesting that with the right combination of strategies, Alzheimer’s could eventually become a manageable or even preventable condition rather than an inevitable decline.
